TipRanks
Advertisement
Advertisement

OCS Stock Latest News

Oculis Holding Announces Board Resignation of Long-Serving Director Lionel Carnot
Company AnnouncementsOculis Holding Announces Board Resignation of Long-Serving Director Lionel Carnot
1d ago
6K
OCS
Oculis price target raised to $39 from $26 at H.C. Wainwright
PremiumThe Fly
Oculis price target raised to $39 from $26 at H.C. Wainwright
14d ago
OCS
Oculis: Advancing Privosegtor in Optic Neuritis and MS Relapses Supports Buy Rating and Unchanged $26 Price Target
PremiumRatings
Oculis: Advancing Privosegtor in Optic Neuritis and MS Relapses Supports Buy Rating and Unchanged $26 Price Target
1M ago
OCS
Oculis price target lowered to $20 from $23 at JPMorgan
PremiumThe Fly
Oculis price target lowered to $20 from $23 at JPMorgan
2M ago
OCS
Oculis to Acquire Full Rights to Privosegtor in Asset Deal with Accure Therapeutics
PremiumCompany Announcements
Oculis to Acquire Full Rights to Privosegtor in Asset Deal with Accure Therapeutics
2M ago
6K
OCS
Oculis price target lowered to $32 from $35 at BofA
PremiumThe FlyOculis price target lowered to $32 from $35 at BofA
2M ago
OCS
Oculis to acquire development, commercial rights to Privosegtor from Accure
Premium
The Fly
Oculis to acquire development, commercial rights to Privosegtor from Accure
2M ago
OCS
Oculis Holding Reports Strong Equity Base and Updates SEC Risk Factors in Q2 2026 Filing
Premium
Company Announcements
Oculis Holding Reports Strong Equity Base and Updates SEC Risk Factors in Q2 2026 Filing
2M ago
6K
OCS
Oculis reports Q2 EPS (16c), consensus (38c)
PremiumThe Fly
Oculis reports Q2 EPS (16c), consensus (38c)
2M ago
OCS
Oculis: Privosegtor’s Pivotal MS Opportunity and FDA Alignment Underpin Unchanged $45 Price Target and Buy Rating
PremiumRatings
Oculis: Privosegtor’s Pivotal MS Opportunity and FDA Alignment Underpin Unchanged $45 Price Target and Buy Rating
2M ago
OCS
Oculis gets FDA pre-IND feedback regarding Privosegtor clinical development plan
PremiumThe Fly
Oculis gets FDA pre-IND feedback regarding Privosegtor clinical development plan
2M ago
OCS
Oculis Advances Privosegtor Into Phase 3 Optic Neuritis Trial: What Investors Should Watch
PremiumCompany Announcements
Oculis Advances Privosegtor Into Phase 3 Optic Neuritis Trial: What Investors Should Watch
3M ago
OCS
Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway
PremiumCompany AnnouncementsOculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway
3M ago
6K
OCS
Oculis price target lowered to $23 from $42 at JPMorgan
Premium
The Fly
Oculis price target lowered to $23 from $42 at JPMorgan
4M ago
OCS
Oculis price target lowered to $38 from $49 at Baird
Premium
The Fly
Oculis price target lowered to $38 from $49 at Baird
4M ago
OCS
Oculis price target lowered to $38 from $49 at Baird
PremiumThe Fly
Oculis price target lowered to $38 from $49 at Baird
4M ago
OCS
Video: Nvidia rallies after taking wraps off new PC processor
PremiumThe Fly
Video: Nvidia rallies after taking wraps off new PC processor
4M ago
AMD
OCS
Oculis price target lowered to $35 from $44 at BofA
PremiumThe Fly
Oculis price target lowered to $35 from $44 at BofA
4M ago
OCS
Oculis price target lowered to $38 from $46 at Needham
PremiumThe Fly
Oculis price target lowered to $38 from $46 at Needham
4M ago
OCS
Oculis price target lowered to $45 from $75 at Guggenheim
PremiumThe FlyOculis price target lowered to $45 from $75 at Guggenheim
4M ago
OCS
Oculis price target lowered to $26 from $47 at H.C. Wainwright
Premium
The Fly
Oculis price target lowered to $26 from $47 at H.C. Wainwright
4M ago
OCS
Oculis price target lowered to $40 from $50 at Stifel
Premium
The Fly
Oculis price target lowered to $40 from $50 at Stifel
4M ago
OCS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >